Oncotelic Therapeutics (OTCQB: OTLC), together with Sapu Nano, announced the publication of a peer-reviewed manuscript in the International Journal of Molecular Sciences validating its proprietary Deciparticle nanoparticle platform. The platform was developed through the creation of Sapu003, an investigational intravenous everolimus formulation currently being evaluated in an ongoing Phase 1b clinical trial. The publication details the platform's formulation design, scalable cGMP manufacturing process, product stability and preclinical performance, demonstrating its potential to enable intravenous delivery of poorly water-soluble therapeutic compounds.
The research published in the International Journal of Molecular Sciences supports broader applications for the Deciparticle platform beyond everolimus, including additional hydrophobic drug candidates. This validation is significant because many promising oncology drugs are poorly water-soluble, limiting their bioavailability and clinical utility. The Deciparticle platform offers a solution by encapsulating these compounds in nanoparticles, allowing for intravenous administration, which can enhance drug delivery and patient outcomes.
Sapu003 is currently being evaluated in a Phase 1b dose-escalation study in patients with advanced mTOR-sensitive solid tumors to assess its safety, pharmacokinetics and preliminary antitumor activity in combination with exemestane. If successful, this could lead to a new treatment option for patients with tumors that are sensitive to mTOR inhibition, a pathway involved in cell growth and proliferation.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on addressing high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates. The company's CEO, Dr. Vuong Trieu, has filed over 500 patent applications and holds 75 issued U.S. patents. Oncotelic also owns 45% of GMP Bio, a joint venture advancing its own pipeline of drug candidates, and develops PDAOAI, a proprietary AI platform for drug discovery and manufacturing.
The publication of this peer-reviewed validation marks a critical step for Oncotelic in establishing the credibility and potential of its Deciparticle platform. For investors and the biomedical community, this development underscores the company's progress in overcoming a key challenge in drug development: the delivery of hydrophobic compounds. By demonstrating a scalable manufacturing process and product stability, Oncotelic is positioning itself to potentially license the platform to other pharmaceutical companies or develop additional drug candidates internally.
The broader implications of this announcement extend to the field of nanomedicine, where nanoparticle-based drug delivery systems are increasingly seen as a way to improve the therapeutic index of existing drugs and enable new treatments. Oncotelic's Deciparticle platform could accelerate the development of intravenous formulations for a range of hydrophobic drugs, potentially improving treatment options for cancer and other diseases.
